Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ExpreS2ion announces financial results for the second quarter 2023

Hørsholm, Denmark, 17 August 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “During the second quarter of 2023, a significant milestone was accomplished with the successful completion of a Phase III clinical trial utilizing our ExpreS2-platform. In mid-June, Bavarian Nordic released 12-month durability data from a Phase II clinical study of the ABNCoV2 capsid virus-

JUHANI LEHTONEN APPOINTED AS MANDATUM’S CHIEF INVESTMENT OFFICER

Mandatum’s Chief Investment Officer will change as the current CIO Ville Talasmäki transitions to the position of Chief Investment Officer of Sampo Group and joins Sampo Group’s Executive Management Group. Senior Portfolio Manager Juhani Lehtonen has been appointed as Mandatum’s new Chief Investment Officer (CIO) and member of Mandatum’s Executive Management Group. The appointments are conditional on the completion of the partial demerger of Sampo Plc, which is estimated to take effect on 1 October 2023. Juhani Lehtonen (MA - Economics, 48), has worked in Mandatum’s portfolio

ExpreS2ion evaluates strategic options for its breast cancer vaccine candidate

Hørsholm, Denmark, 17 August 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces that the Board has decided to assess strategic options for the ES2B-C001 breast cancer project, aimed at conserving capital resources to further advance the company’s exploratory vaccine pipeline and technology platforms.The decision follows initial considerations taking into account limited funding options in challenging capital markets, an expected delay in the clinical trial application (CTA) due to the need for further GMP manufacturing preparations,

Nightingale Health rolls out remote blood collection kit for medical research and clinical trials

Nightingale Health Plc, Press release, 17 August 2023 at 9:55 a.m. (EEST)  Nightingale Health Plc (“Nightingale Health”), a technology company promoting preventative health with its proprietary health risk detection platform, has rolled out a remote blood collection kit for its medical research and clinical trial customers. This launch follows the company’s acquisition of the worldwide license and rights to the Velvet™ self-collection device in January 2023.   Nightingale Kit and its self-collection device allow study participants to draw their own blood sample from a finger-prick.

SmartCraft ASA (SMCRT) - Invitation to presentation of second quarter 2023 results and deep dive presentation

17 August 2023 - SmartCraft ASA will publish its second quarter 2023 financial report on Thursday 24 August 2023 at 07:00 CET together with the Q2 2023 presentation material on the company website and www.newsweb.no. Investors, analysts, and journalists are welcome to join to an English language webcast presentation of the report followed by a deep-dive presentation of the company's go-to-market model and development strategy on the same day, Thursday 24 August 2023, at 08:00 CET. Webcast link: https://channel.royalcast.com/landingpage/hegnarmedia/20230824_2/ Presenters: ·

MyFirstApp Sweden AB (publ) Interim Report 2 - 2023

This is pressrelease and interim report is a translation from the main language which is Swedish. Financial overview +-----------------------------+-------+-------+-------+-------+----+|Consolidated income statement|Q2 2023|Q2 2022|H1 2023|H1 2022|2022|+-----------------------------+-------+-------+-------+-------+----+|Net revenue (msek) | 0,7| 0| 0,9| 0| 0,4|+-----------------------------+-------+-------+-------+-------+----+|EBITDA (msek) | −0,9| 0| −1,6| 0| 0,1|+-----------------------------+-------+-------+-------

Billerud introduces new regional organization for Europe and appoints acting CFO

Billerud is introducing a new organization whereby the company harmonizes and operates its business in two distinct geographical regions - Europe and North America. Billerud further appoints Andrei Krés as acting CFO, effective immediately. Matthew Hirst, previously EVP Commercial, has been appointed President of Billerud Europe and will lead the new European organization consisting of Commercial, Operations and Procurement & Wood Supply functions. Kevin Kuznicki remains President of the North American organization.  "I’m pleased that Matthew has taken the position of leading the

Erik Selin strengthens his ownership in Checkin.com

Swedish businessman Erik Selin, through the company Erik Selin Fastigheter AB and ES Aktiehandel AB, today extends his ownership in Checkin.com Group (STO:CHECK). The two companies have today together purchased 1.25 million shares from Lessac AB, the company’s largest owner that is controlled by Checkin.com CEO and Co-Founder Kristoffer Cassel.“We want strategic, experienced and long-term owners and hence it feels exciting that Erik wants to strengthen his ownership in Checkin.com. As the company’s largest owner I will always prioritize what is right long-term and build a strong Checkin.

Cereno Scientific shares invitation to the Capital Markets Day 2023 on August 30, 2023

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced further information about the company’s upcoming Capital Markets Day that will be held on August 30, 2023. We invite analysts, investors, and financial media to join us for insights into our strategy and operations.The Capital Markets Day will be held on Wednesday, August 30, 2023, starting at 08:30 in central Stockholm. Coffee and refreshments will be served from 08:00. The Capital Markets Day will be held at Haymarket by Scandic, Hötorget

WINDOWMASTER HALF-YEAR REPORT 2023

Company Announcement No. 38-2023 - Interim report (full H1-2023 report).  Vedbæk, 17 august 2023Financial Highlights H1 2023 – Recovery in May and June after weak start to the year · Order intake decreased 9% (decreased 1% excluding OEM) to DKK 128.2m in H1 2023 (H1 2022: DKK 140.6m) · Revenue decreased 3% (increased 3% excluding OEM) to DKK 114.8m in H1 2023 (H1 2022: DKK 117.8m) · EBITDA decreased 80% to DKK 1.3 (H1 2022: DKK 6.5m) corresponding to an EBITDA margin of 1.3% (H1 2022: 5.5%) · The outlook for 2023 is maintained. Revenue is still expected to be in the range

Half year Report January - June 2023

April – June 2023- Net Sales MSEK 133 (124)- Order intake *) MSEK 170 (240)- Operating profit (EBITDA) MSEK 19.2 (17.7)- Operating profit (EBIT) MSEK 5.6 (7.1)- Total Comprehensive income MSEK 27.9 (27.5)- Earnings per share, before and after dilution (SEK) 0.32 (0.01)- Cash flow from operating activities MSEK -19.3 (30.8) January – June 2023- Net Sales MSEK 246 (238)- Order intake *) MSEK 260 (323)- Operating profit (EBITDA) MSEK 20.7 (33.3)- Operating profit (EBIT) MSEK -3.0 (12.7)- Total Comprehensive income MSEK 14.4 (39.8)- Earnings per share, before and

BCIX finds upgrade path to 400G networking with Smartoptics

Oslo, Norway – August 17, 2023 – Smartoptics, a leading provider of optical networking solutions, today announced that Berlin Commercial Internet Exchange (BCIX), Berlin’s leading internet exchange point, has chosen Smartoptics to increase 100G capacity between data centers. The solution also provides a cost-efficient and future-proof upgrade path to 400G.Berlin Commercial Internet Exchange (BCIX) is a neutral, not-for-profit internet exchange providing peering and interconnection services in Berlin. The internet exchange actively engages with a community of people interested in technology

Minesto publishes Half-Year Report 2023

CEO Dr Martin Edlund:” With the second quarter, we further accelerate our focus on driving large-scale, project-based sales of tidal energy arrays, where reference installations of our smaller power plant Dragon 4 are the key to long term business.”Significant events April-June 2023 At the end of May, Minesto initiated the installation of the first megawatt-unit, Dragon 12 (1.2 MW). The first phase of the offshore installation of Dragon 12 was successfully completed in Vestmanna, Faroe Islands. The 3.4 km main subsea cable was laid on the seabed, from the onshore grid connection point to

Wyld Networks brings forward publication of financial report for Q2 2023

Publication of Wyld Networks report for the second quarter will be brought forward to August 21, 2023. The previously announced date for publication was August 30, 2023.The reason why the company is bringing forward the financial report is that the financial statements will be ready faster than expected and that the Board therefore sees no reason to delay publication.   For further information about Wyld Networks, please contact: Alastair Williamson, CEO Wyld NetworksE-mail: alastair.williamson@wyldnetworks.comTel: +44 7 824 997 689   About Wyld Networks Wyld Networks

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q2 2023

"Our strategic transformation to become a chemical company has continued according to plan during the second quarter. Binder sales in Nonwoven & fiber technologies continued to grow sharply, and our consumer products in Green coatings & maintenance products also showed good growth. On the other hand, sales of OrganoWood timber in Functional wood dropped heavily because of the weak construction activity. All in all, the group’s sales grew by 6 percent to MSEK 41.0 (38.5)."Translation from CEO Mårten Hellbergs comments to the Interim Report. Q2, 1 April - 30 June 2023 The Group compared

Jacob Lund joins Investor as Head of Corporate Communication & Sustainability

Jacob Lund, currently Head of Global Media Relations at AstraZeneca, has been appointed new Head of Corporate Communication & Sustainability and member of the Executive Leadership Team at Investor. Jacob has most recently worked for ten years at AstraZeneca where he has held several leading communication positions including Head of Chair Office, Head of Corporate Affairs Sweden & Nordics and Head of Corporate Affairs Global Sustainability. He has also been a member of AstraZeneca’s Global Sustainability leadership team. Before joining AstraZeneca, Jacob led the Media practice in Sweden at

TORM plc Q2 2023 results, dividend distribution, and financial outlook 2023

“During the second quarter of 2023, we experienced a continued healthy rate environment, contributing to a profit before tax of USD 184m compared to USD 107m in the same period last year,” says Jacob Meldgaard and continues: “Based on this, we will return USD 126.6m to our shareholders as dividends for the period.” Financial results In the second quarter of 2023, TORM saw a 23% increase in TCE per day to 36,360 USD/day (2022, same period: 29,622 USD per day) as a result of higher freight rates. TCE earnings reached USD 308.0m (2022, same period; USD 209.6m) and EBITDA increased 54% to

BioStock: Neola CEO sees exciting autumn ahead

As Neola Medical reports its second quarter of 2023, much of the focus is on market preparations. Intensive work is underway with technical verification studies while the company is also preparing for both a preclinical and a clinical study. BioStock contacted CEO Hanna Sjöström to find out more about how she views the development during the quarter.Read the full article at biostock.se : https://www.biostock.se/en/2023/08/neola-ceo-sees-exciting-autumn-ahead/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nordea cancels repurchased shares

Nordea Bank AbpStock exchange release – Total number of voting rights and capital17 August 2023 at 9.15 EET Nordea has today cancelled 9,635,610 treasury shares in line with the decision by the Board of Directors. The shares were held for capital optimisation purposes and acquired through share buy-backs. The cancellation brings the total number of shares in Nordea to 3,569,745,018. The total number of votes attached to the shares is 3,569,745,018. The cancellation of the shares was registered with the Finnish Trade Register on 17 August 2023. The company holds 1,976,528

Dignitana AB Publishes Q2 2023 Interim Report

15 percent revenue growth driven by improved utilization Financial highlights Q2 2023 · Net sales amounted to 21.1 MSEK (18.3), an increase of 15 percent over the same period in 2022 · Operating result amounted to -4.7 MSEK (+0.1). · Net result after financial items amounted to -4.7 MSEK (-0.2). · Earnings per share were-0.07 SEK (0.00). · Cash Balance amounted to 5.4 MSEK (7.3). · Average Daily Treatment Revenue (ADTR)* was 241 TSEK (201), an increase of 20 percent over the same period in 2022. Business highlights during the period · Dignitana announced a

Penneo achieves 25% year-on-year ARR growth in H1-2023

Company Announcement No. 27-2023Copenhagen, 17 August 2023Interim financial report for the period 1 January 2023 - 30 June 2023H1-2023 performance highlights · ARR increased by 8.3M DKK to 79.2M DKK corresponding to 25% year-on-year (YoY) growth at the end of the quarter · ARR increase from Newbiz amounted to 4.3M DKK compared to 4.8M DKK in H1-2022 · ARR increase from Uplift amounted to 5.3M DKK compared to 4.0M DKK in H1-2022 · ARR lost to Churn amounted to 1.2M DKK compared to 0.7M DKK in H1-2022 · ARR from foreign markets increased by 2.4M DKK compared to 3.3M DKK

AnaCardio receives IND approval from the FDA for AC01 to Start a Clinical Pharmacology Study

PRESS RELEASE Stockholm, Sweden, August 17, 2023AnaCardio, a Swedish clinical-stage biopharmaceutical company focussing on developing novel contractile agents to treat patients with heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for the investigational drug AC01. The approval enables expansion of the clinical development program for AC01 to the US, and to initiate a study in healthy volunteers. This study will evaluate the effects of food on the pharmacokinetics of orally administered

Interim Report for 2nd Quarter 2023

Revenues increased 37% and EBIT increased 208%Key Facts for the 2[nd] Quarter 2023 (1[st] April 2023 – 30[th] June 2023) Revenues increased 37% and EBIT increased 208% All figures are compared to the same quarter last year if not explicitly stated otherwise. · Revenues increased by 36.54% to €9,458,630 (€6,927,414). · EBIT increased by 207.95% to €676,489 (-€626,662). · EBIT margin of 7.15% (-9.05%). · Customer deposits increased by 16.35% to €17,688,865 (€15,202,758). · 30,990 new registered customers (91,142), decrease of 66%. · 9,646 new depositing customers (14,

FlashBet App Rights Acquisition and Equity Issue

17 August 2023 ChallengerX plc                                                            (“ChallengerX”, “CXS" or the Company") FlashBet App Rights Acquisition and Equity Issue ChallengerX  (AQUIS: CXS), the company that employs both traditional and non-traditional marketing strategies to rapidly “professionalise” amateur and semi-professional sports clubs around the world, is pleased to announce that it has entered into an exclusive licence agreement with Flash Corp Technologies Ltd (“Flash Corp”) by which the Company has acquired a renewable 13-month license over the rights

There are no items matching the current filter
There are no more items matching the current filter
Back to top